

# Jayesh Desai

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9214827/jayesh-desai-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

200  
papers

13,593  
citations

44  
h-index

115  
g-index

208  
ext. papers

16,925  
ext. citations

5.5  
avg, IF

5.86  
L-index

#	Paper	IF	Citations
200	Evaluation of baseline BRAF V600E mutation in circulating tumor DNA and efficacy response from the BEACON study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 162-162	2.2	1
199	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.. <i>Targeted Oncology</i> , <b>2022</b> , 17, 95	5	1
198	ATRT-17. A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumours and atypical teratoid rhabdoid tumours.. <i>Neuro-Oncology</i> , <b>2022</b> , 24, i6-i7	1	
197	Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. <i>ESMO Open</i> , <b>2022</b> , 7, 100477	6	1
196	The Role of Systemic Therapies in the Management of Soft Tissue Sarcoma <b>2021</b> , 169-188		
195	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , <b>2021</b> , 127, 2934-2942	6.4	11
194	Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9047-9047	2.2	3
193	Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , <b>2021</b> , 92, 493-499	4.3	1
192	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 58	9.8	1
191	Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. <i>Cancer</i> , <b>2021</b> , 127, 884-893	6.4	8
190	A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 87, 613-620	3.5	
189	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 273-284	2.2	60
188	BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?. <i>Targeted Oncology</i> , <b>2021</b> , 16, 227-236	5	2
187	Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.. <i>JCO Precision Oncology</i> , <b>2021</b> , 5, 1160-1165	3.6	1
186	Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases. <i>Current Oncology</i> , <b>2021</b> , 28, 3659-3667	2.8	3
185	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.. <i>ESMO Open</i> , <b>2021</b> , 6, 100328	6	2
184	Therapeutic strategies to remodel immunologically cold tumors.. <i>Clinical and Translational Immunology</i> , <b>2020</b> , 9, e1226	6.8	1

183	Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2140-2150	2.2	28
182	Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. <i>Lung Cancer</i> , <b>2020</b> , 146, 310-317	5.9	11
181	CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research. <i>JCO Clinical Cancer Informatics</i> , <b>2020</b> , 4, 136-146	5.2	
180	A Malignant Neoplasm From the Jejunum With a Fusion and 26-Year Survival History. <i>International Journal of Surgical Pathology</i> , <b>2020</b> , 28, 553-562	1.2	9
179	Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective. <i>Cost Effectiveness and Resource Allocation</i> , <b>2020</b> , 18, 5	2.4	2
178	Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 8-8	2.2	19
177	Using Genomic Sequencing to Explain an Exceptional Response to Therapy in a Malignant Phyllodes Tumor.. <i>JCO Precision Oncology</i> , <b>2020</b> , 4, 1263-1266	3.6	1
176	Recurrent fusions in pediatric sarcoma and brain tumors. <i>Journal of Physical Education and Sports Management</i> , <b>2020</b> , 6,	2.8	2
175	New biomarkers for checkpoint inhibitor therapy. <i>ESMO Open</i> , <b>2020</b> , 5, e000597	6	8
174	CD8 tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous metastatic colorectal carcinoma do not track with survival. <i>Clinical and Translational Immunology</i> , <b>2020</b> , 9, e1155	6.8	3
173	KRAS Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1207-1217	59.2	469
172	Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 165-172	1.6	1
171	First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427). <i>Contemporary Clinical Trials Communications</i> , <b>2019</b> , 16, 100409	1.8	7
170	Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1632-1643	59.2	481
169	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 394, 478-487	40	148
168	Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1134-1142	10.3	59
167	Wither surgical oncology?. <i>ANZ Journal of Surgery</i> , <b>2019</b> , 89, 10-11	1	
166	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1460-1469	2.2	114

165	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. <i>Scientific Reports</i> , <b>2019</b> , 9, 14551	4.9	16
164	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. <i>Nature</i> , <b>2019</b> , 575, 217-223	50.4	703
163	Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression. <i>Pathology</i> , <b>2019</b> , 51, 655-657	1.6	5
162	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , <b>2019</b> , 3, pkz071	4.6	2
161	Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 1940-1945	15.9	19
160	Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e18236-e18236	2.2	1
159	Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 688-688	2.2	12
158	MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)Based combinations in gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS467-TPS467	2.2	7
157	BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 358-358	2.2	22
156	The value of networks in driving phase I trials: the Peter MacCallum Cancer Centre experience. <i>Chinese Clinical Oncology</i> , <b>2019</b> , 8, 23	2.3	
155	OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, S208	8.9	25
154	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , <b>2019</b> , 9, 354-369	24.4	60
153	Novel Vaccine Targeting Colonic Adenoma: a Pre-clinical Model. <i>Journal of Gastrointestinal Surgery</i> , <b>2019</b> , 23, 626-633	3.3	2
152	Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3465-3474	12.9	10
151	A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 1026-1036	4.3	16
150	Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. <i>Internal Medicine Journal</i> , <b>2018</b> , 48, 786-794	1.6	3
149	Systematic Review of Clinical Outcomes Following Various Treatment Options for Patients with Extraabdominal Desmoid Tumors. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 1544-1554	3.1	18
148	BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, v109	10.3	8

147	ATRT-27. A PHASE II STUDY OF PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH SOLID TUMORS INCLUDING MALIGNANT RHABDOID TUMOR/ATYPICAL TERATOID RHABDOID TUMOURS. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i33-i33	1	78
146	An Update on Immunotherapy for Solid Tumors: A Review. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 3404-3412	3.12	43
145	A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 1060-1071	4.3	19
144	Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors. <i>Cancer Discovery</i> , <b>2018</b> , 8, 988-1005	24.4	27
143	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 313-319	3.8	6
142	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 11502-11502	2.2	14
141	A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2515-2515	2.2	12
140	Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4123-4123	2.2	38
139	BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4512-4512	2.2	14
138	Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TP53113-TP53113	2.2	1
137	A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 560-560	2.2	27
136	Precision oncology using a clinician-directed, tailored approach to molecular profiling. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2018</b> , 14, 84-90	1.9	1
135	Treatment of patients with primary retroperitoneal sarcoma: predictors of outcome from an Australian specialist sarcoma centre. <i>ANZ Journal of Surgery</i> , <b>2018</b> , 88, 1151-1157	1	8
134	Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 82, 887-898	3.5	6
133	ASO Author Reflections: Immunotherapy for Solid Tumors: A Review. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 974-975	3.1	25
132	A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 886-894	4.3	14
131	Nivolumab for the treatment of colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 611-618	3.5	24
130	Variations of Surveillance Practice for Patients with Bone Sarcoma: A Survey of Australian Sarcoma Clinicians. <i>Sarcoma</i> , <b>2017</b> , 2017, 1837475	3.1	1

129	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1182-1191	21.7	1317
128	Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , <b>2017</b> , 16, e45-e54	3.8	6
127	Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 88-98	1.6	14
126	Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3548-3548	2.2	4
125	A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFM) metastatic colorectal (mCRC): The EVICT (Erlotinib and Vemurafenib in Combination Trial) study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3557-3557	2.2	12
124	Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3572-3572	2.2	1
123	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 519-519	2.2	42
122	Utilization of systemic therapy options in the routine treatment of metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 738-738	2.2	
121	Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 785-785	2.2	
120	First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. <i>Targeted Oncology</i> , <b>2016</b> , 11, 149-56	5	1
119	Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer. <i>Oncolmmunology</i> , <b>2016</b> , 5, e1149667	7.2	8
118	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 346ra92	17.5	688
117	Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services. <i>Clinical Sarcoma Research</i> , <b>2016</b> , 6, 11	2.5	12
116	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> , <b>2016</b> , 16, 339	4.8	11
115	Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2016</b> , 15, e9-e15	3.8	37
114	A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3066-3066	2.2	2
113	Nivolumab + ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3501-3501	2.2	70
112	Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3502-3502	2.2	90

111	The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3511-3511	2.2	3
110	Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFM CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3544-3544	2.2	51
109	First-in-man trial of 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid (PENAO) as a continuous intravenous infusion (CIVI), in patients (pt) with advanced solid tumours.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e14025-e14025	2.2	4
108	Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 685-685	2.2	
107	Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 671-8	7.5	47
106	Survival impact of the Australian National Bowel Cancer Screening Programme. <i>Internal Medicine Journal</i> , <b>2016</b> , 46, 166-71	1.6	9
105	Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3488-98	12.9	20
104	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2258-64	2.2	41
103	Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1715-22	10.3	373
102	Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3216-29	12.9	47
101	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4032-8	2.2	424
100	Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 979-88	8.7	21
99	Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. <i>Targeted Oncology</i> , <b>2015</b> , 10, 179-88	5	28
98	A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. <i>Targeted Oncology</i> , <b>2015</b> , 10, 99-109	5	36
97	Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2015</b> , 11, 262-71	1.9	3
96	A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells. <i>PLoS ONE</i> , <b>2015</b> , 10, e0144559	3.7	38
95	Wiki-based clinical practice guidelines for the management of adult onset sarcoma: a new paradigm in sarcoma evidence. <i>Sarcoma</i> , <b>2015</b> , 2015, 614179	3.1	8
94	Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. <i>Journal of Cancer Epidemiology</i> , <b>2015</b> , 2015, 189132	2.8	12

93	Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival. <i>Clinical Colorectal Cancer</i> , <b>2015</b> , 14, 185-91	3.8	28
92	Maxillofacial osteosarcoma: outcomes and update of current treatment protocols. <i>International Journal of Oral and Maxillofacial Surgery</i> , <b>2015</b> , 44, e53	2.9	
91	Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. <i>Acta Oncologica</i> , <b>2015</b> , 54, 487-92	3.2	35
90	Survival impact of adjuvant chemotherapy for resected early-stage rectal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 712-712	2.2	
89	KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2014</b> , 10, 261-5	1.9	4
88	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). <i>Annals of Oncology</i> , <b>2014</b> , 25, 1032-8	10.3	174
87	A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 2254-61	8.7	39
86	What is the future potential of the PI3K pathway in colorectal cancer treatment?. <i>Colorectal Cancer</i> , <b>2014</b> , 3, 113-116	0.8	
85	Controversies in the management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2014</b> , 10, 216-27	1.9	4
84	An Australasian perspective on sarcoma research, translational biology and clinical trials: the Australasian Sarcoma Study Group (ASSG). <i>Pathology</i> , <b>2014</b> , 46, 160-3	1.6	1
83	Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. <i>Cancer Research</i> , <b>2014</b> , 74, 921-31	10.1	18
82	Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2014</b> , 10, 361-7	1.9	5
81	Personalized management: inoperable gastrointestinal stromal tumors. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 130-4	6.9	2
80	A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2524-2524	2.2	8
79	A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9051-9051	2.2	36
78	Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e14558-e14558	2.2	1
77	Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e14536-e14536	2.2	
76	Delivery and effectiveness of adjuvant therapy for stage III colon cancer in routine clinical practice.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e14540-e14540	2.2	1



75	Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e17637-e17637	2.2	2.2
74	Prognostic impact of clinicopathologic features in metastatic rectal versus colon cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e14518-e14518	2.2	
73	Are the survival benefits associated with primary resection in de novo metastatic colorectal cancer (mCRC) mediated by reversal of systemic inflammation?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 464-464	2.2	
72	Regular aspirin (ASA) use and survival in patients with PIK3CA-mutated metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 386-386	2.2	1
71	Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 85, 121-35	7	17
70	Intra-patient dose escalation in Ewing sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review. <i>Clinical Sarcoma Research</i> , <b>2013</b> , 3, 15	2.5	5
69	Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 657-67	12.9	205
68	SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. <i>Cancer Research</i> , <b>2013</b> , 73, 725-35	10.1	202
67	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 1785-93	0.7	98
66	Developing a national database for metastatic colorectal cancer management: perspectives and challenges. <i>Internal Medicine Journal</i> , <b>2013</b> , 43, 1224-31	1.6	26
65	PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3285-96	12.9	94
64	Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/βcatenin signalling thresholds for tumourigenesis. <i>Oncogene</i> , <b>2013</b> , 32, 4675-82	9.2	93
63	The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> ,	7.1	25
62	Massively parallel sequencing (MPS) of circulating DNA in patients with metastatic colorectal cancer (mCRC): Prognostic significance and early changes during chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 11015-11015	2.2	1
61	Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC)?. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 410-410	2.2	1
60	On-treatment progression-free survival analysis of aflibercept-FOLFIRI treatment within 28 days of progression in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 469-469	2.2	2
59	Soft-tissue sarcomas in the Asia-Pacific region: a systematic review. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2013</b> , 14, 6821-32	1.7	10
58	Impact of diabetes on clinicopathologic and genetic features of colorectal cancer formation.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 426-426	2.2	

57	Metastatic colorectal cancer and management in public versus private hospitals: Similarities and differences.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 497-497	2.2	
56	Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS2619-TPS2619	2.2	
55	Aspirin use and survival outcomes in patients (pts) with PIK3CA mutant colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3598-3598	2.2	
54	Understanding why some people with stage III colon cancer do not receive adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e14608-e14608	2.2	
53	On-treatment progression-free survival analysis of ziv-aflibercept/FOLFIRI treatment within 28 days of end of treatment in metastatic colorectal cancer: Updated efficacy results from the VELOUR study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3573-3573	2.2	
52	Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2012</b> , 8, 43-52	1.9	4
51	Outcomes of patients with maxillofacial osteosarcoma: a review of 15 cases. <i>Journal of Oral and Maxillofacial Surgery</i> , <b>2012</b> , 70, 734-9	1.8	12
50	An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2633-2637	10.3	8
49	Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1849-56	2.2	169
48	Microsatellite instability status is critical to analysis of survival in stage II colon cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 675-6; author reply 676-7	2.2	3
47	Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. <i>Critical Reviews in Oncogenesis</i> , <b>2012</b> , 17, 51-67	1.3	36
46	Patterns of care according to treatment intent for metastatic colorectal cancer (mCRC): A 2.5-year review of routine practice.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e16516-e16516	2.2	
45	Clinicopathologic and molecular associations of PIK3CA and PTEN mutation in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3623-3623	2.2	
44	Optimising the management of soft tissue tumours. <i>Pathology</i> , <b>2011</b> , 43, 295-301	1.6	0
43	Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody. <i>Medical Oncology</i> , <b>2011</b> , 28 Suppl 1, S162-4	3.7	9
42	Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. <i>BMC Cancer</i> , <b>2011</b> , 11, 313	4.8	9
41	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. <i>Cancer</i> , <b>2011</b> , 117, 4623-32	6.4	492
40	Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 2075-84	7.5	169

39	Response assessment in gastrointestinal stromal tumor. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 1251-5	12.9	12
38	KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1122-30	12.9	161
37	Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5152-60	12.9	42
36	Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 416-26	12.9	93
35	Patient comorbidities and behaviour once diagnosed are major contributors to disparities in cancer health outcomes. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e36-7; author reply e38	2.2	6
34	Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy. <i>Analytical Biochemistry</i> , <b>2010</b> , 406, 41-50	3.1	7
33	PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3534-3534	2.2	135
32	Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7642-7651	12.9	320
31	Impact of body mass index on colorectal cancer treatment and outcomes: need for prospective and comprehensive data. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1524-6	2.2	4
30	Response to "Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting". <i>Oncologist</i> , <b>2009</b> , 14, 104-5; author reply 106-7	5.7	
29	Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 426-31	7.5	29
28	Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. <i>Clinical Endocrinology</i> , <b>2008</b> , 69, 669-724	3.4	83
27	DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 8061-9	12.9	67
26	Re: Residual treatment disparities after oncology referral for rectal cancer. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 1739; author reply 1740	9.7	2
25	Patient age and comorbidity are major determinants of adjuvant chemotherapy use for stage III colon cancer in routine clinical practice. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4516-7; author reply 4517-8	2.2	30
24	Clinical use of therapies targeting tumor vasculature and stroma. <i>Current Cancer Drug Targets</i> , <b>2008</b> , 8, 498-508	2.8	10
23	Consensus approaches to best practice management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2008</b> , 4, 188-198	1.9	3
22	Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. <i>Cancer</i> , <b>2007</b> , 109, 1863-9	6.4	67

21	Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management*. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2007</b> , 3, 167-176	1.9	10
20	Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5398-405	12.9	100
19	Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2643-50	12.9	189
18	Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. <i>Lancet, The</i> , <b>2007</b> , 370, 2011-9	40	843
17	Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2325-31	2.2	329
16	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. <i>Lancet, The</i> , <b>2006</b> , 368, 1329-38	40	2004
15	Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 864-70	7.5	19
14	Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. <i>Annals of Internal Medicine</i> , <b>2006</b> , 145, 660-4	8	295
13	Recombinant human erythropoietin in cancer-related anemia: an evidence-based review. <i>Best Practice and Research in Clinical Haematology</i> , <b>2005</b> , 18, 389-406	4.2	14
12	Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. <i>Radiology</i> , <b>2005</b> , 235, 892-8	20.5	120
11	Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3006-3006	2.2	4
10	Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 9011-9011	2.2	66
9	Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 5732-40	12.9	89
8	SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3001-3001	2.2	35
7	Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3010-3010	2.2	3
6	Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 9024-9024	2.2	14
5	SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3001-3001	2.2	22
4	Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3010-3010	2.2	5

3	Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 9024-9024	2.2	7
2	Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors. <i>Current Treatment Options in Oncology</i> , <b>2002</b> , 3, 489-96	5.4	14
1	Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. <i>British Journal of Cancer</i> , <b>2002</b> , 86, 12-3	8.7	53